Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex plaintiff pool narrowed

Executive Summary

U.S. District Judge Charles Breyer rules that plaintiffs "have not presented scientifically reliable evidence that Celebrex causes heart attacks or strokes when ingested at the 200 mg a day dose." A Nov. 19 decision will permit testimony on the 400 mg dose and whether Pfizer's COX-2 inhibitor is capable of causing strokes, noting that the latter question "is close." The case, In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, is pending in the Northern District of California...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel